Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 340

1.

Impact of the Anticancer Drug NT157 on Tyrosine Kinase Signaling Networks.

Su SP, Flashner-Abramson E, Klein S, Gal M, Lee RS, Wu J, Levitzki A, Daly RJ.

Mol Cancer Ther. 2018 May;17(5):931-942. doi: 10.1158/1535-7163.MCT-17-0377. Epub 2018 Feb 12.

PMID:
29440449
2.

PSMA-targeted polyinosine/polycytosine vector induces prostate tumor regression and invokes an antitumor immune response in mice.

Langut Y, Talhami A, Mamidi S, Shir A, Zigler M, Joubran S, Sagalov A, Flashner-Abramson E, Edinger N, Klein S, Levitzki A.

Proc Natl Acad Sci U S A. 2017 Dec 26;114(52):13655-13660. doi: 10.1073/pnas.1714587115. Epub 2017 Dec 11.

3.

S101, an Inhibitor of Proliferating T Cells, Rescues Mice From Superantigen-Induced Shock.

Shir A, Klein S, Sagiv-Barfi I, Geiger T, Zigler M, Langut Y, Edinger N, Levitzki A.

J Infect Dis. 2018 Jan 4;217(2):288-297. doi: 10.1093/infdis/jix576.

PMID:
29149330
4.

PSMA-homing dsRNA chimeric protein vector kills prostate cancer cells and activates anti-tumor bystander responses.

Langut Y, Edinger N, Flashner-Abramson E, Melamed-Book N, Lebendiker M, Levi-Kalisman Y, Klein S, Levitzki A.

Oncotarget. 2017 Apr 11;8(15):24046-24062. doi: 10.18632/oncotarget.15733.

5.

Targeting polyIC to EGFR over-expressing cells using a dsRNA binding protein domain tethered to EGF.

Edinger N, Lebendiker M, Klein S, Zigler M, Langut Y, Levitzki A.

PLoS One. 2016 Sep 6;11(9):e0162321. doi: 10.1371/journal.pone.0162321. eCollection 2016.

6.

HER2-Targeted Polyinosine/Polycytosine Therapy Inhibits Tumor Growth and Modulates the Tumor Immune Microenvironment.

Zigler M, Shir A, Joubran S, Sagalov A, Klein S, Edinger N, Lau J, Yu SF, Mizraji G, Globerson Levin A, Sliwkowski MX, Levitzki A.

Cancer Immunol Res. 2016 Aug;4(8):688-97. doi: 10.1158/2326-6066.CIR-15-0203. Epub 2016 May 30.

7.

Targeting colorectal cancer via its microenvironment by inhibiting IGF-1 receptor-insulin receptor substrate and STAT3 signaling.

Sanchez-Lopez E, Flashner-Abramson E, Shalapour S, Zhong Z, Taniguchi K, Levitzki A, Karin M.

Oncogene. 2016 May 19;35(20):2634-44. doi: 10.1038/onc.2015.326. Epub 2015 Sep 14.

8.

Targeting melanoma with NT157 by blocking Stat3 and IGF1R signaling.

Flashner-Abramson E, Klein S, Mullin G, Shoshan E, Song R, Shir A, Langut Y, Bar-Eli M, Reuveni H, Levitzki A.

Oncogene. 2016 May 19;35(20):2675-80. doi: 10.1038/onc.2015.229. Epub 2015 Jun 29.

PMID:
26119932
9.

The tyrphostin NT157 suppresses insulin receptor substrates and augments therapeutic response of prostate cancer.

Ibuki N, Ghaffari M, Reuveni H, Pandey M, Fazli L, Azuma H, Gleave ME, Levitzki A, Cox ME.

Mol Cancer Ther. 2014 Dec;13(12):2827-39. doi: 10.1158/1535-7163.MCT-13-0842. Epub 2014 Sep 29.

10.

Transmembrane signaling in Saccharomyces cerevisiae as a model for signaling in metazoans: state of the art after 25 years.

Engelberg D, Perlman R, Levitzki A.

Cell Signal. 2014 Dec;26(12):2865-78. doi: 10.1016/j.cellsig.2014.09.003. Epub 2014 Sep 15. Review.

PMID:
25218923
11.

Optimization of liganded polyethylenimine polyethylene glycol vector for nucleic acid delivery.

Joubran S, Zigler M, Pessah N, Klein S, Shir A, Edinger N, Sagalov A, Razvag Y, Reches M, Levitzki A.

Bioconjug Chem. 2014 Sep 17;25(9):1644-54. doi: 10.1021/bc500252a. Epub 2014 Aug 14.

PMID:
25121341
12.

EGF receptor family: twisting targets for improved cancer therapies.

Burgess AW, Henis YI, Hynes NE, Jovin T, Levitzki A, Pinkas-Kramarski R, Yarden Y.

Growth Factors. 2014 Apr;32(2):74-81. doi: 10.3109/08977194.2014.896355. Epub 2014 Mar 18.

PMID:
24641597
13.

Degrasyn-like symmetrical compounds: possible therapeutic agents for multiple myeloma (MM-I).

Peng Z, Maxwell DS, Sun D, Bhanu Prasad BA, Schuber PT Jr, Pal A, Ying Y, Han D, Gao L, Wang S, Levitzki A, Kapuria V, Talpaz M, Young M, Showalter HD, Donato NJ, Bornmann WG.

Bioorg Med Chem. 2014 Feb 15;22(4):1450-8. doi: 10.1016/j.bmc.2013.12.048. Epub 2014 Jan 3.

14.

Therapeutic destruction of insulin receptor substrates for cancer treatment.

Reuveni H, Flashner-Abramson E, Steiner L, Makedonski K, Song R, Shir A, Herlyn M, Bar-Eli M, Levitzki A.

Cancer Res. 2013 Jul 15;73(14):4383-94. doi: 10.1158/0008-5472.CAN-12-3385. Epub 2013 May 7.

15.

Targeted cancer immunotherapy.

Zigler M, Shir A, Levitzki A.

Curr Opin Pharmacol. 2013 Aug;13(4):504-10. doi: 10.1016/j.coph.2013.04.003. Epub 2013 May 3. Review.

PMID:
23648271
16.

Heterogeneity of gene expression in murine squamous cell carcinoma development-the same tumor by different means.

Cohen N, Kravchenko-Balasha N, Klein S, Levitzki A.

PLoS One. 2013;8(3):e57748. doi: 10.1371/journal.pone.0057748. Epub 2013 Mar 18.

17.

Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance.

Levitzki A.

Annu Rev Pharmacol Toxicol. 2013;53:161-85. doi: 10.1146/annurev-pharmtox-011112-140341. Epub 2012 Oct 8. Review.

PMID:
23043437
18.

Targeting the Immune System to Fight Cancer Using Chemical Receptor Homing Vectors Carrying Polyinosine/Cytosine (PolyIC).

Levitzki A.

Front Oncol. 2012 Feb 8;2:4. doi: 10.3389/fonc.2012.00004. eCollection 2012.

19.

On a fundamental structure of gene networks in living cells.

Kravchenko-Balasha N, Levitzki A, Goldstein A, Rotter V, Gross A, Remacle F, Levine RD.

Proc Natl Acad Sci U S A. 2012 Mar 20;109(12):4702-7. doi: 10.1073/pnas.1200790109. Epub 2012 Mar 5.

20.

PolyIC GE11 polyplex inhibits EGFR-overexpressing tumors.

Abourbeh G, Shir A, Mishani E, Ogris M, Rödl W, Wagner E, Levitzki A.

IUBMB Life. 2012 Apr;64(4):324-30. doi: 10.1002/iub.1002. Epub 2012 Feb 23.

21.

Studying protein-peptide interactions using benzophenone units: a case study of protein kinase B/Akt and its inhibitor PTR6154.

Tal-Gan Y, Naveh S, Klein S, Moshel O, Levitzki A, Gilon C.

Anal Biochem. 2012 Feb 15;421(2):750-4. doi: 10.1016/j.ab.2011.11.032. Epub 2011 Nov 29.

PMID:
22197420
22.

Tyrphostin-like compounds with ubiquitin modulatory activity as possible therapeutic agents for multiple myeloma.

Peng Z, Pal A, Han D, Wang S, Maxwell D, Levitzki A, Talpaz M, Donato NJ, Bornmann W.

Bioorg Med Chem. 2011 Dec 1;19(23):7194-204. doi: 10.1016/j.bmc.2011.09.057. Epub 2011 Oct 7.

PMID:
22036213
23.

A novel small molecule deubiquitinase inhibitor blocks Jak2 signaling through Jak2 ubiquitination.

Kapuria V, Levitzki A, Bornmann WG, Maxwell D, Priebe W, Sorenson RJ, Showalter HD, Talpaz M, Donato NJ.

Cell Signal. 2011 Dec;23(12):2076-85. doi: 10.1016/j.cellsig.2011.08.002. Epub 2011 Aug 9.

PMID:
21855629
24.

Metabolic stability of peptidomimetics: N-methyl and aza heptapeptide analogs of a PKB/Akt inhibitor.

Tal-Gan Y, Freeman NS, Klein S, Levitzki A, Gilon C.

Chem Biol Drug Des. 2011 Nov;78(5):887-92. doi: 10.1111/j.1747-0285.2011.01207.x. Epub 2011 Sep 26.

PMID:
21824328
25.

Nucleic acid-based therapeutics for glioblastoma.

Shir A, Levitzki A, Wagner E, Klein S, Ogris M.

Anticancer Agents Med Chem. 2011 Oct;11(8):693-9. Review.

PMID:
21707501
26.

Backbone cyclic peptide inhibitors of protein kinase B (PKB/Akt).

Tal-Gan Y, Hurevich M, Klein S, Ben-Shimon A, Rosenthal D, Hazan C, Shalev DE, Niv MY, Levitzki A, Gilon C.

J Med Chem. 2011 Jul 28;54(14):5154-64. doi: 10.1021/jm2003969. Epub 2011 Jun 22.

PMID:
21650457
27.

Convergence of logic of cellular regulation in different premalignant cells by an information theoretic approach.

Kravchenko-Balasha N, Remacle F, Gross A, Rotter V, Levitzki A, Levine RD.

BMC Syst Biol. 2011 Mar 16;5:42. doi: 10.1186/1752-0509-5-42.

28.

Microwave-assisted solid-phase aza-peptide synthesis: aza scan of a PKB/Akt inhibitor using aza-arginine and aza-proline precursors.

Freeman NS, Tal-Gan Y, Klein S, Levitzki A, Gilon C.

J Org Chem. 2011 May 6;76(9):3078-85. doi: 10.1021/jo102422x. Epub 2011 Apr 5.

PMID:
21410283
29.

Contribution of gross chromosomal changes to HPV16-induced transformation.

Kravchenko-Balasha N, Klein S, Safrai M, Levitzki A.

Mol Biosyst. 2011 May;7(5):1501-11. doi: 10.1039/c0mb00284d. Epub 2011 Feb 24.

PMID:
21350750
30.

Up-regulation of AMP-activated protein kinase in cancer cell lines is mediated through c-Src activation.

Mizrachy-Schwartz S, Cohen N, Klein S, Kravchenko-Balasha N, Levitzki A.

J Biol Chem. 2011 Apr 29;286(17):15268-77. doi: 10.1074/jbc.M110.211813. Epub 2011 Jan 18.

31.

EGFR-homing dsRNA activates cancer-targeted immune response and eliminates disseminated EGFR-overexpressing tumors in mice.

Shir A, Ogris M, Roedl W, Wagner E, Levitzki A.

Clin Cancer Res. 2011 Mar 1;17(5):1033-43. doi: 10.1158/1078-0432.CCR-10-1140. Epub 2010 Dec 30.

32.

Amino acid starvation sensitizes cancer cells to proteasome inhibition.

Mizrachy-Schwartz S, Cohen N, Klein S, Kravchenko-Balasha N, Levitzki A.

IUBMB Life. 2010 Oct;62(10):757-63. doi: 10.1002/iub.377.

33.

Status of p53 in human cancer cells does not predict efficacy of CHK1 kinase inhibitors combined with chemotherapeutic agents.

Zenvirt S, Kravchenko-Balasha N, Levitzki A.

Oncogene. 2010 Nov 18;29(46):6149-59. doi: 10.1038/onc.2010.343. Epub 2010 Aug 23.

PMID:
20729914
34.

Poly(I:C)-mediated tumor growth suppression in EGF-receptor overexpressing tumors using EGF-polyethylene glycol-linear polyethylenimine as carrier.

Schaffert D, Kiss M, Rödl W, Shir A, Levitzki A, Ogris M, Wagner E.

Pharm Res. 2011 Apr;28(4):731-41. doi: 10.1007/s11095-010-0225-4. Epub 2010 Aug 6.

PMID:
20694527
35.

Design, synthesis, and evaluation of quinazoline T cell proliferation inhibitors.

Sagiv-Barfi I, Weiss E, Levitzki A.

Bioorg Med Chem. 2010 Sep 1;18(17):6404-13. doi: 10.1016/j.bmc.2010.07.004. Epub 2010 Jul 8.

PMID:
20674367
36.

Information-theoretic analysis of phenotype changes in early stages of carcinogenesis.

Remacle F, Kravchenko-Balasha N, Levitzki A, Levine RD.

Proc Natl Acad Sci U S A. 2010 Jun 1;107(22):10324-9. doi: 10.1073/pnas.1005283107. Epub 2010 May 17.

37.

Signal transduction therapy of cancer.

Levitzki A, Klein S.

Mol Aspects Med. 2010 Aug;31(4):287-329. doi: 10.1016/j.mam.2010.04.001. Epub 2010 May 6. Review.

PMID:
20451549
38.

Synthesis and structure-activity relationship studies of peptidomimetic PKB/Akt inhibitors: the significance of backbone interactions.

Tal-Gan Y, Freeman NS, Klein S, Levitzki A, Gilon C.

Bioorg Med Chem. 2010 Apr 15;18(8):2976-85. doi: 10.1016/j.bmc.2010.02.031. Epub 2010 Feb 23.

PMID:
20347317
39.

Novel method for the synthesis of urea backbone cyclic peptides using new Alloc-protected glycine building units.

Hurevich M, Tal-Gan Y, Klein S, Barda Y, Levitzki A, Gilon C.

J Pept Sci. 2010 Apr;16(4):178-85. doi: 10.1002/psc.1218.

PMID:
20196085
40.

A color discriminating broad range cell staining technology for early detection of cell transformation.

Sagiv I, Idelevich P, Rivkin I, Margalit R, Elkeles A, Levitzki A.

J Carcinog. 2009;8:16. doi: 10.4103/1477-3163.58372.

41.

The complex regulation of HIC (Human I-mfa domain containing protein) expression.

Reiss-Sklan E, Levitzki A, Naveh-Many T.

PLoS One. 2009 Jul 7;4(7):e6152. doi: 10.1371/journal.pone.0006152.

42.

Shift from apoptotic to necrotic cell death during human papillomavirus-induced transformation of keratinocytes.

Kravchenko-Balasha N, Mizrachy-Schwartz S, Klein S, Levitzki A.

J Biol Chem. 2009 Apr 24;284(17):11717-27. doi: 10.1074/jbc.M900217200. Epub 2009 Feb 16.

43.

Targeting the EGFR and the PKB pathway in cancer.

Klein S, Levitzki A.

Curr Opin Cell Biol. 2009 Apr;21(2):185-93. doi: 10.1016/j.ceb.2008.12.006. Epub 2009 Feb 11. Review.

PMID:
19216065
44.

Anomalous features of EMT during keratinocyte transformation.

Geiger T, Sabanay H, Kravchenko-Balasha N, Geiger B, Levitzki A.

PLoS One. 2008 Feb 6;3(2):e1574. doi: 10.1371/journal.pone.0001574.

45.

Optimization of energy-consuming pathways towards rapid growth in HPV-transformed cells.

Mizrachy-Schwartz S, Kravchenko-Balasha N, Ben-Bassat H, Klein S, Levitzki A.

PLoS One. 2007 Jul 11;2(7):e628.

47.

The effect of the [18F]-PEG group on tracer qualification of [4-(phenylamino)-quinazoline-6-YL]-amide moiety--an EGFR putative irreversible inhibitor.

Dissoki S, Aviv Y, Laky D, Abourbeh G, Levitzki A, Mishani E.

Appl Radiat Isot. 2007 Oct;65(10):1140-51. Epub 2007 May 8.

PMID:
17574425
48.

Subunit S5a of the 26S proteasome is regulated by antiapoptotic signals.

Gus Y, Karni R, Levitzki A.

FEBS J. 2007 Jun;274(11):2815-31. Epub 2007 Apr 25.

49.

Targeted cancer therapy: promise and reality.

Klein S, Levitzki A.

Adv Cancer Res. 2007;97:295-319. Review.

PMID:
17419951
50.

A novel substrate mimetic inhibitor of PKB/Akt inhibits prostate cancer tumor growth in mice by blocking the PKB pathway.

Litman P, Ohne O, Ben-Yaakov S, Shemesh-Darvish L, Yechezkel T, Salitra Y, Rubnov S, Cohen I, Senderowitz H, Kidron D, Livnah O, Levitzki A, Livnah N.

Biochemistry. 2007 Apr 24;46(16):4716-24. Epub 2007 Mar 31.

PMID:
17397140

Supplemental Content

Loading ...
Support Center